Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,446 total articles
Aduro Clean Technologies has made significant progress in its paraffinic crude program by securing yellow and black paraffinic crude feedstocks from Uinta Basin sources and completing a new lab-scale continuous-flow unit. The expansion and consolidation of its London facility support ongoing Technology Demonstration stages aimed at improving proces…
Anavex Life Sciences Corp. announced preliminary financial results for Q2 2026, showing reduced net loss and increased cash resources supporting operations into 2028. The company is prioritizing its lead compound blarcamesine (ANAVEX®2-73) across three CNS indications: early Alzheimer's disease, Rett syndrome, and Fragile X syndrome, and is engagin…
Enlivex Ltd., a Nasdaq-listed company, announced a significant surge in trading volume on its Rain protocol, reaching $860 million in July 2026, representing a 622% month-over-month increase from June. The company expects the Rain protocol's trading volumes to grow exponentially in the coming years, forecasted to reach $33 billion by 2029, driving …
Diginex Limited announced it has regained compliance with Nasdaq's minimum bid price requirement after its stock price stayed at or above $1.00 for 20 consecutive business days, thus preserving its Nasdaq listing status. This marks recovery from a previous warning received in March 2026 due to its share price falling below the required threshold. D…
Innventure, Inc., an industrial growth conglomerate listed on NASDAQ under the ticker INV, announced it will release its Q2 2026 financial results on August 13, 2026. The release will be followed by a conference call including remarks from the incoming CEO Dr. Bill Grieco and CEO of Accelsius, John Hewitt. The company focuses on building scalable i…
Aligos Therapeutics, a clinical-stage biopharmaceutical company specializing in therapies for liver and viral diseases, announced it will release its Q2 2026 financial results on August 6, 2026, prior to U.S. market open. The company focuses on developing treatments for conditions like chronic hepatitis B virus infection.
Gentherm, a leader in thermal management and pneumatic comfort technologies, announced its participation in two upcoming investor conferences, including a fireside chat at the J.P. Morgan Auto Conference and hosting investors at the Seaport Annual Summer Investor Conference. The events aim to provide insights into the company's performance and outl…
Aureus Greenway Holdings Inc. (Nasdaq: PUSA) has filed a Form S-4 registration statement with the SEC as part of its proposed business combination with Autonomous Power Corporation (dba Powerus). The merger aims to position the combined entity as a leader in domestically produced defense autonomy and counter-drone technology. The combined company w…
Nuwellis, Inc. announced acceptance of a retrospective study in Frontiers in Pediatrics demonstrating that epoprostenol is a safe and feasible alternative anticoagulant for Aquadex ultrafiltration therapy in critically ill pediatric patients. This supports broader adoption of Aquadex therapy and offers clinicians an additional tool for complicated …
Vericel Corporation announced robust second quarter 2026 financial results with a 22% revenue increase to $77.5 million led by strong growth in MACI and Burn Care products. The company raised its full-year revenue guidance to $330-$340 million and authorized a $200 million share repurchase program, reflecting confidence in continued growth. Positiv…
Stantec, partnered with Johnson, Mirmiran and Thompson, secured a $150 million joint venture contract from the U.S. Army Corps of Engineers to design more than eight miles of integrated coastal storm risk management infrastructure on Charleston's peninsula. The project includes storm surge barriers, floodwalls, levees, pump stations, and nature-bas…
Crescent Biopharma reported strong second-quarter 2026 results highlighting progress in multiple clinical trials for its novel cancer therapies, including CR-001, CR-002, and CR-003. The company completed a $143.7 million public offering, extending its cash runway into mid-2028, supporting ongoing development and upcoming clinical data readouts in …
Dragonfly Energy Holdings Corp., a leading US lithium battery technology company known for its Battle Born Batteries brand, will release its second quarter 2026 financial and operational results after market close on August 6, 2026. A conference call and live webcast will follow for investors and other interested parties. The company continues to f…
Leonardo DRS delivered robust Q2 2026 results with 10% revenue growth and a 59% increase in net earnings year-over-year. The company increased its 2026 adjusted EBITDA and adjusted diluted EPS guidance, supported by a record funded backlog of $5.1 billion. The $450 million acquisition of Raft enhances its AI, data fusion, and mission software capab…
SIGA Technologies, a commercial-stage pharmaceutical company specializing in infectious disease treatments, has scheduled a webcast and conference call for August 6, 2026, to discuss its second-quarter financial results and provide a business update. The call will be led by CEO Diem Nguyen and CFO Daniel Luckshire, and is accessible via webcast and…
Wave Life Sciences reported its Q2 2026 financial results, highlighting progress in its RNA-based drug pipeline including dosing initiation in Phase 2a obesity trial (WVE-007), a scheduled FDA meeting for accelerated approval pathway for its AATD therapy (WVE-006), and upcoming clinical trial application for its liver disease candidate (WVE-008). T…
Saia, Inc. announced its second quarter 2026 financial results, highlighting a 17.1% increase in revenue to $956.5 million, a 26.0% increase in operating income to $125.2 million, and diluted earnings per share of $3.51, up from $2.67 in Q2 2025. The company saw growth in LTL shipments and tonnage, maintained a low claims ratio, improved operating …
DT Midstream, Inc. announced strong financial results for Q2 2026 including a net income and operating earnings of $112 million, or $1.09 per diluted share. Adjusted EBITDA reached $305 million for the quarter. The company declared a $0.88 per share dividend and reaffirmed its 2026 Adjusted EBITDA guidance of $1.155 to $1.225 billion and 2027 outlo…
Laureate Education, Inc. announced robust financial results for Q2 2026, including 17% revenue growth to $615.9 million and a 40% increase in net income compared to Q2 2025. The company also reported a 10% increase in new enrollments and a 6% increase in total enrollments for the first half of 2026. Due to strong operating momentum and favorable cu…
FTI Consulting reported record second quarter 2026 revenues of $993.5 million, a 5.3% increase year-over-year driven by growth in Corporate Finance, Technology, and Forensic and Litigation Consulting segments. Despite higher revenues, net income decreased primarily due to increased costs, and GAAP EPS fell to $1.99 from $2.13 last year. Adjusted EP…
InflaRx N.V., a Nasdaq-listed biopharmaceutical company specializing in anti-inflammatory therapeutics targeting the complement system, will report its second quarter 2026 financial and operating results on August 6, 2026, before market open. The company focuses on developing treatments like izicopan and vilobelimab for inflammatory and renal disea…
Tvardi Therapeutics has selected ulcerative colitis (UC) as the first clinical indication for its oral STAT3 inhibitor, TTI-109, after positive results from a Phase 1 healthy volunteer study demonstrating immunomodulatory effects on immune cell populations implicated in UC pathogenesis. The company plans to initiate a moderate-to-severe UC clinical…
Mobilicom Limited announced a significant design win with an Israeli defense technology company developing AI-enabled autonomous weapon systems. The company has delivered integrated software and hardware, including cybersecurity software (OS3), electronic warfare resistance (ICE), secure datalinks (SkyHopper), and ground control stations. This desi…
Palvella Therapeutics announced that its Chief Scientific Officer, Dr. Jeffrey Martini, has been invited to provide public comments at an upcoming FDA public workshop focused on drug repurposing. The meeting will address selection criteria and regulatory considerations for advancing repurposed therapies, particularly targeting rare and chronic dise…
Alterity Therapeutics announced an FDA End-of-Phase 2 meeting outcome confirming a clear regulatory pathway for its drug ATH434 targeting Multiple System Atrophy (MSA). The FDA accepted a single pivotal Phase 3 trial plus confirmatory evidence to support approval, with Phase 3 trial initiation planned by the end of 2026. The company also reported c…
